UCB : La COVID-19 décale la revue d’approbation de bimekizumab
>Décalage de l’approbation de bimekizumab - Nous apprenions ce week-end que la FDA décalait l’approbation de bimekizumab dans le traitement du psoriasis modéré à sévère. La FDA n’a pas été en mesure d’inspecter les installations européennes de fabrication du bimekizumab qui est un prérequis obligatoire avant une approbation sur le marché américain. L’explication émise est à mettre à la charge des restrictions de voyage liées au COVID-19. Selon la société, la FD...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.